Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

McGill University

$110,000.00

Poor adherence to cardiovascular medications and its clinical consequences: are some medications more "forgiving" than others?

EF 2013-14

Résumé
Medications are the primary tools used to effectively manage chronic diseases. However, the effects of medications are highly dependent on the actual behaviours of patients. Studies have demonstrated that more than 50% of medications are not taken as prescribed, leading to disastrous consequences, both economic and clinical. Recently, it has been suggested that instead of trying to change the behaviours of patients, which requires multiple resources (and has a limited effect), research should focus on strategies to limit the clinical consequences of poor adherence. This is where this study makes a contribution. We are going to test the forgiving hypothesis by exploring if the risk of having a cardiovascular event, such as a stroke or a myocardial infarction, is different when a poorly adherent patient is taking a more forgiving agent. Forgiveness refers to the fact that some medications could be better able than others to maintain therapeutic action over time when doses are missed. To achieve our goal, two steps will be followed. In the first step, we are going to elaborate and validate a forgiveness index for every antihypertensive agent, as well as statins and antiplatelet agents, three classes of medications that are commonly used for the prevention of cardiovascular events, using a consensus approach with experts in cardiology. In the second step, we are going to test our hypothesis by using pharmacy refills to evaluate adherence to medication and forgiveness index of the medication, and administrative databases to evaluate the risk of cardiovascular events. A cohort of patients will be followed during a 3-year period to assess if the risk of an event is modified by the score on the forgiveness index. This study will be the first step toward the elaboration of a research program aimed at developing and evaluating electronic tools to adequately manage poorly adherent patients.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
301117
Name
Motulsky Aude
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Allied Health Professionals - Fellowships
Projecttitle
Poor adherence to cardiovascular medications and its clinical consequences: are some medications more "forgiving" than others?
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$110,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adherence; Cardiovascular Events; Cardiovascular Medications; Clinical And Administrative Databases; Health Informatics; Pharmacological Properties Of Medications
Abstract
Medications are the primary tools used to effectively manage chronic diseases. However, the effects of medications are highly dependent on the actual behaviours of patients. Studies have demonstrated that more than 50% of medications are not taken as prescribed, leading to disastrous consequences, both economic and clinical. Recently, it has been suggested that instead of trying to change the behaviours of patients, which requires multiple resources (and has a limited effect), research should focus on strategies to limit the clinical consequences of poor adherence. This is where this study makes a contribution. We are going to test the forgiving hypothesis by exploring if the risk of having a cardiovascular event, such as a stroke or a myocardial infarction, is different when a poorly adherent patient is taking a more forgiving agent. Forgiveness refers to the fact that some medications could be better able than others to maintain therapeutic action over time when doses are missed. To achieve our goal, two steps will be followed. In the first step, we are going to elaborate and validate a forgiveness index for every antihypertensive agent, as well as statins and antiplatelet agents, three classes of medications that are commonly used for the prevention of cardiovascular events, using a consensus approach with experts in cardiology. In the second step, we are going to test our hypothesis by using pharmacy refills to evaluate adherence to medication and forgiveness index of the medication, and administrative databases to evaluate the risk of cardiovascular events. A cohort of patients will be followed during a 3-year period to assess if the risk of an event is modified by the score on the forgiveness index. This study will be the first step toward the elaboration of a research program aimed at developing and evaluating electronic tools to adequately manage poorly adherent patients.
Competitiondate
201311
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Motulsky, Aude
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $110,000~ $0~